Daiichi Sankyo And AstraZeneca To Present Results From Interim Analysis Of DESTINY-PanTumor02 Phase 2 Trial Of ENHERTU At ASCO
Portfolio Pulse from Benzinga Newsdesk
Daiichi Sankyo and AstraZeneca will present interim results from the DESTINY-PanTumor02 Phase 2 trial of ENHERTU at the American Society of Clinical Oncology (ASCO) conference.
June 05, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca and Daiichi Sankyo will present interim results from the DESTINY-PanTumor02 Phase 2 trial of ENHERTU at the ASCO conference.
The presentation of positive interim results from the DESTINY-PanTumor02 Phase 2 trial of ENHERTU at the ASCO conference could potentially boost AstraZeneca's stock price in the short term, as it demonstrates progress in their partnership with Daiichi Sankyo and the development of ENHERTU.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100